Mckesson Corporation

Mckesson Corporation

MCK

Get informed when a big investor buys or sells

+ Follow
Market Cap$89.24B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Mckesson CorporationMckesson Corporation190.43%69%0.21.2

Earnings Call Q4 2026

May 7, 2026 - AI Summary

Strong FY2026 performance + shareholder returns (all segments momentum) - McKesson reported fiscal 2026 adjusted EPS (diluted) of $39.11, +18% YoY, and adjusted operating profit +15% to $6.5B on revenue of $403B (+12% YoY). - Operating cash flow: $6.2B (exceeded plan) and free cash flow: $5.4B. - Capital returned to shareholders: $5.1B in FY2026 via share repurchases + dividends; highlighted ROIC 34% and ~$23B returned since fiscal 2020 with 17% adjusted EPS CAGR.
FY2027 outlook: core growth expected but not uniform across all businesses - Company guided FY2027 adjusted EPS to $43.80–$44.60 (+12% to +14% YoY), with first-half vs second-half cadence broadly similar to FY2026 (some quarter volatility tied to discrete tax timing). - Segment expectations: - North American Pharmaceutical: revenue +4% to +8%, operating profit +5.5% to +9.5%; continued GLP-1 growth expected with quarter-to-quarter variability. - Oncology & Multispecialty: revenue +14.5% to +18.5%, operating profit +13.5% to +17.5% (benefiting from provider expansion and integration of PRISM Vision and Core Ventures). - Prescription Technology Solutions (RxTS): revenue +2.5% to +6.5%, operating profit +11% to +15% (profit strength despite slower top-line growth variability). - Medical-Surgical Solutions (toward separation): revenue +1% to +6%, operating profit flat to +4%.
Major strategic progress: oncology platform scaling + Medical-Surgical separation execution - Oncology & multispecialty platform growth drivers - U.S. Oncology Network added 570+ providers in FY2026 (largest net increase since 2010); +1,900+ providers using Ambient Scribe. - PRISM Vision: ~+20% provider growth and added new practices (e.g., Spokane Eye Clinic; Retina Macula Institute in May). - Integration update: acquisitions (PRISM Vision, Core Ventures) contributed meaningfully to growth (company cited ~34% of segment operating profit growth). - Medical-Surgical separation - Progress milestone: Norway fully exited (completed in January). - For separation readiness: financing put in place ($1B Term Loan A + $1B revolving credit facility) and Apollo agreed as a minority investor (~13% stake; ~$1.25B, valuing NewCo at ~$13B EV; subject to approvals). - Expected separation-related additional term loans: up to $2.25B in 2H of Q1 FY2027; company expects separation to unlock “strategic clarity” and shareholder value.

Exclusive for Stockcircle Pro members

Sign upSign Up
$1006.00

Target Price by Analysts

36% upsideMckesson Target Price DetailsTarget Price
$1580.55

Current Fair Value

113.7% upside

Undervalued by 113.7% based on the discounted cash flow analysis.

Share Statistics

Market cap$89.24 Billion
Enterprise Value$93.88 Billion
Dividend Yield$3.17 (0.43%)
Earnings per Share$38.55
Beta0.36
Outstanding Shares122,100,000

Return

Return on Equity68.85%ROE
Return on Assets5.78%
Return on Invested Capital41.23%

Valuation & Multiples

P/E Ratio19.04P/E Ratio
PEG56.84PEG
Price to Sales0.22Price to Sales
Price to Book Ratio13.21Price to Book Ratio
Enterprise Value to Revenue0.23
Enterprise Value to EBIT14.88
Enterprise Value to Net Income19
Total Debt to Enterprise0.09
Debt to Equity1.25Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 14, 2026
EPS Estimate
$11.36
Average shareholder expectation
Revenue Estimate
$101.35 B
Average shareholder expectation

Next Earnings Call

Expected Date
August 5, 2026
EPS Estimate
$9.58
Average shareholder expectation
Revenue Estimate
$103.99 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio1.1218▲ 26.53%
Total Calls507,218▼ 35.25%
Total Puts568,993▼ 15.20%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %86.09%▼ 2.27%
Total Invested$91.59B▲ 2.77%
Investors Holding2,074▲ 28.00%

ESG Score

No data

About Mckesson Corporation

80,000 employees
CEO: Brian Tyler

McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information solutions. McKesson partners with pharmaceutical manufacturers, p...

Relevant Senate Committees

Joint Committee on Taxation

This committee provides critical analysis and revenue estimates for tax legislation, directly influencing corporate tax policy and the overall tax burden on McKesson's profitability and capital investments.

Finance

This powerful committee controls taxation, trade, and entitlement spending (e.g., Medicare, Medicaid), all of which directly and profoundly impact McKesson's corporate profitability, supply chain costs, and customer base.

Appropriations

This committee directly allocates federal spending, including for healthcare programs, which dictates the funding streams for federal customers and beneficiaries that McKesson serves, making it highly relevant.

Health, Education, Labor, and Pensions

This committee has direct oversight of the FDA (impacting pharmaceutical distribution), NIH (influencing future products), and labor laws, all of which critically affect McKesson's operations and the products it handles.

Special Committee on Aging

This committee's discussions on drug pricing and long-term care significantly impact the pharmaceutical and healthcare services sectors, which are core to McKesson's distribution and specialty care businesses.

Veterans' Affairs

McKesson is a major supplier of medical products and services. Funding decisions for the Department of Veterans Affairs directly impact government healthcare contractors like McKesson, making this committee highly relevant.